CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, MPM Capital (“MPM”), one of the world’s leading biotech investment firms, announced that it has raised $850 million for its second Oncology Impact Fund (“OIF ...

MPM Capital announced the close of its second oncology impact fund earlier this month, raising US$850 million to invest in companies—mostly early-stage—that are developing treatments and cures for ...

“We are delighted to announce the addition of Detlev to our investment committee,” said Ansbert Gadicke, M.D., MPM Managing Director. “Detlev’s leadership experience combined with the depth of his ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Cambridge venture capital and creation firm MPM Capital has ...

Pharma-focused mobile clinical trial data collection company Clinical Ink has merged with CentrosHealth, formerly MyHealthBook, which makes configurable mobile apps for clinical trial patient ...

Brooklyn Park-based CHF Solutions Inc., a private medical device manufacturer, has closed a $26.2 million Series D equity financing, led by MPM Capital of San Francisco. Five other firms also ...

Boston-based venture capital firm MPM Capital has participated in the $25 million Series C closing funding round of Menlo Park, Calif., company ForteBio Inc. ForteBio, an analytical systems provider ...

NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Leaps by Bayer, Bayer AG’s impact investment arm, and ...

Dr. Christiana (Chris) Bardon leads MPM's public market investing as portfolio manager for BioImpact Equities and the Oncology Impact Funds. MPM Capital is a world-leading biotechnology investment ...